Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

doi:10.1182/blood-2016-02-699520

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

Blood - 14 Jul 2016

Assouline Sarit E, Nielsen Torsten Holm, Yu Stephen, Alcaide Miguel, Chong Lauren, MacDonald David, Tosikyan Axel, Kukreti Vishal, Kezouh Abbas, Petrogiannis-Haliotis Tina, Albuquerque Marco, Fornika Daniel, Alamouti Sepideh, Froment Remi, Greenwood Celia M T, Oros Kathleen Klein, Camglioglu Errol, Sharma Ayushi, Christodoulopoulos Rosa, Rousseau Caroline, Johnson Nathalie, Crump Michael, Morin Ryan D, Mann Koren K

Abstract excerpt

The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg orally 3 times...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxamic Acids

Share to Indoles

Share to Lymphoma, Large B-Cell, Diffuse

Share to MEF2 Transcription Factors

Share to Neoplasm Proteins

Share to Recurrence

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 27166360
DOI: 10.1182/blood-2016-02-699520
PMCID: PMC4972610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.PMID 27166360Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy ResistanceSemantic proximity Read ↗

Novel therapeutic targets in diffuse large B-cell lymphomaSemantic proximity Read ↗

Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular PhenotypeSemantic proximity Read ↗

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.Semantic proximity Read ↗

Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.Semantic proximity Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Lymphoma: turning biology into cures.Semantic proximity Read ↗

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.